Arca
Skip to content
Tools
Tools

ITGAL, ITGB2: Integrin alpha-L/beta-2 (LFA-1)

Complex in Homo sapiens that 3 drugs act on.

  • Drugs that act on it: 3
  • Approved: 2
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on ITGAL, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Antibody 2

Approved2

  • Lifitegrast
  • Efalizumab

Phase 30

    Phase 21

    • Rovelizumab

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      LifitegrastApprovedBausch & LombSmall moleculeAntagonistIntegrin alpha-L/beta-2 (LFA-1) antagonist5
      EfalizumabWithdrawnApprovedMerck KGaA, Darmstadt, GermanyAntibodyInhibitorIntegrin alpha-L/beta-2 (LFA-1) inhibitor1
      RovelizumabPhase 2—AntibodyAntagonistIntegrin alpha-L/beta-2 (LFA-1) antagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 6 in all, from ClinicalTrials.gov.
      Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal MicroscopyLifitegrastPhase 4Not yet recruitingToyos ClinicMay 1, 2026
      This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry EyeLifitegrastPhase 4Not yet recruitingPittsburgh Research InstituteMar 24, 2026
      Switching From Xiidra to TRYPTYRLifitegrastPhase 4Not yet recruitingSouthern College of OptometryDec 5, 2025
      Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye DiseaseLifitegrastPhase 3RecruitingLunan Better Pharmaceutical Co., LTD.Mar 17, 2025
      Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical MedicationsLifitegrast—RecruitingUniversity of California, Los AngelesApr 21, 2020
      PsoBest - The German Psoriasis RegistryEfalizumab—RecruitingUniversitätsklinikum Hamburg-EppendorfMay 7, 2013

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364172, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.